Learn how a stem cell transplant presents a promising leukemia treatment option in this article. [Read more…]
Option-based Collaboration to Develop Two CAR T-Cell Product Candidates Using Fate’s Proprietary iPSC Product Platform
SAN DIEGO, Sept. 17, 2018 — Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that it has entered into a collaboration with ONO Pharmaceutical Co., Ltd. for the joint development and commercialization of two off-the-shelf CAR-T cell product candidates. Using Fate Therapeutics’ proprietary induced pluripotent stem cell (iPSC) product platform, the two CAR T-cell collaboration candidates will each be derived from a clonal master iPSC line engineered to completely eliminate endogenous TCR expression, insert a chimeric antigen receptor (CAR) into the TRAC locus and incorporate other anti-tumor functionality. [Read more…]
Can T cells be an effective approach to cancer treatment? CAR T-cell therapy, as this cutting-edge treatment is called, uses a patient’s own immune system to help fight cancers in the body. The result is a natural treatment that proves effective against a variety of blood cancers and may have hope for other cancers in the future as well.
T-cells are the workhorses of our immune system and they play a key role in directing the immune response and killing cells infected by pathogens.
Using T Cells For Cancer Treatment
In this article:
- CAR-T Cell Therapy Treatments for Treatment of Cancer
- What Causes Cancer?
- How Does the Immune System Work – and What Are Its Limits?
- What Is Immunotherapy?
- Are There Different Types of Immunotherapy?
- What Are T Cells?
- What Is CAR-T Cell Therapy?
- How Does CAR-T Cell Therapy Work?
- Who Is CAR-T Cell Therapy Right For?
- Why Doesn’t CAR-T Cell Therapy Work for Solid Tumors?
- Are There Any Risks?
- What Are the Benefits of CAR-T?
- How Effective Is CAR-T Treatment?
- Progress in CAR-T Cell Therapy Development
Allogene Therapeutics, a clinical-stage biotechnology company pioneering the development of allogeneic CAR T therapies for cancer, announced that it completed a $120 million private financing of Convertible Notes.
According to the company, “Allogene is advancing its allogeneic CAR T cell portfolio, which includes rights to 16 preclinical CAR T cell therapy targets and U.S. rights to UCART19, an allogeneic CAR T cell therapy candidate that is being developed for the treatment of CD19-expressing hematological malignancies. In partnership with Servier, UCART19 is in Phase 1 development for the treatment of relapsed/refractory acute lymphoblastic leukemia (ALL).” [Read more…]